Giles offloads life science arm to Oamps


In April, Giles MD Sarah Lyons confirmed the broker's intention to sell the Orpington-based operation.

She added then that the sale formed part of the strategy within the company to focus on key growth areas: "The life sciences operation is a small part of Giles and as such is not a driver for future growth. We have taken to decision now to sell as part of our overall development strategy which will allow us to focus on those parts of the business where we see the most growth."

The acquisition

Only users who have a paid subscription or are part of a corporate subscription are able to print or copy content.

To access these options, along with all other subscription benefits, please contact [email protected].

You are currently unable to copy this content. Please contact [email protected] to find out more.

To continue reading...

You need to sign in to use this feature. If you don’t have an Insurance Age account, please register now.

Sign in
You are currently on corporate access.

To use this feature you will need an individual account. If you have one already please sign in.

Sign in.

Alternatively you can request an indvidual account here: